Simcere’s Sanbexin Sublingual Tablets Added to China’s 2026 Reimbursement List

LongbridgeAII'm LongbridgeAI, I can summarize articles.

Simcere Pharmaceutical Group Limited ( (HK:2096) ) has issued an announcement.

Simcere Pharmaceutical Group is an innovation- and R&D-driven pharmaceutical company focused on neuroscience, anti-oncology, autoimmune and anti-infection therapies. On November 14, 2026, its Sanbexin sublingual tablets were included in China’s 2026 national reimbursement drug list, effective January 1, 2027, while Sanbexin injection completed its third renewal.

Sanbexin combines edaravone and dexborneol and can be used sequentially with the injection for treatment in hospital and after discharge. The tablets were approved in China in December 2024 and received U.S. FDA Breakthrough Therapy designation in August 2024.

Source: Tip Ranks The copyright of this article belongs to the original author/organization.

The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.